Description
Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms from which it has already progressed two products into clinical development. The first, SuliXen, is a long-acting insulin and the second, ErepoXen, is a long-acting erythropoietin (EPO). Lipoxen’s preclinical pipeline includes Factor XIII and vaccines against HIV, influenza and malaria. The Company has a low-risk business model and currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, Genentech, Amgen and Genzyme.
Share Price
In-depth Lipoxen Plc Proactive Investors Articles
More news ►Recent Lipoxen Plc news
- 01/03/2010 Lipoxen and Serum Institute of India start Phase II trial for ErepoXen
- 01/03/2010 Lipoxen and Serum Institute of India start Phase II trial for anaemia treatment ErepoXen
- 08/02/2010 Lipoxen granted EU patent for polysialic acid technology StimuXen
- 05/02/2010 Lipoxen H2 revenue hit by EPO and Insulin delays, foresees positive news flow in 2010
- 14/01/2010 Lipoxen's PolyXen bio-polymer technology wins US Patent
Presentations & Company Media
No Documents available.
Related Research & Media
No Documents available.
Company Statement:
Lipoxen develops and commercialises high-value, differentiated protein, vaccine and anti-cancer drug product candidates. The company’s strategy is to identify product candidates and to take them from an early stage of development into clinical trials.
At the appropriate stage of clinical development, Lipoxen outlicenses these protein, vaccine and anti-cancer drug product candidates to a partner. Partners are selected according to their ability to complete late phase clinical trials, obtain relevant regulatory approvals, manufacture the products and market them effectively.
Lipoxen’s technologies in focus are, PolyXen® and ImuXen® which are used as a platform for the company to:
* Develop its own protein, vaccine and anti-cancer new product candidates
* Co-develop new product candidates with partners
* Enable partners to improve their proprietary products
* Help partners to manage their product lifecycles more effectively
Current Operations:
Lipoxen has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Lipoxen’s technologies include:
PolyXen® for protein drug delivery
PolyXen® is a versatile enabling technology that uses the biopolymer polysialic acid to prolong the active life and improve the pharmacokinetics of therapeutic peptides and proteins, as well as conventional small molecule drugs. PolyXen® is potentially a next generation method to PEGylation for the delivery of protein drugs. (Read More)
ImuXen® for vaccine delivery
ImuXen® is an advanced enabling technology that uses liposome-based constructs to boost the effectiveness of DNA, protein and polysaccharide vaccines. ImuXen® can achieve protective immunity in a single dose. (Read More)
Lipoxen's new product candidates
Lipoxen is also developing its own range of proprietary product candidates, based on products already in the market and which incorporate these new technologies. Product candidates which are currently under development include:
| ErepoXen® | Potential treatment to maintain the red blood cell population and prevent anaemia |
| StimuXen™ | Potential treatment for neutropenia (a deficiency in white blood cells associated with myelosuppressive chemotherapy) |
| InferoXen ® | Potential treatment for hepatitis C |
| SuliXen® | Potential treatment for type II diabetes |
| LipoNeu™ | Potential vaccine for streptococcus pneumoniae (a cause of meningitis in children and pneumonia in adults) |
| LipoTet™ | Potential oral tetanus vaccine |
| HepaXen™ | Potential hepatitis B vaccine |
| LipoRab™ | Potential rabies vaccine |
| LipoTaxen® | Potential anti-cancer drug |
Management
Sir Brian Richards, CBE, BSc, PhD, DSc - Non-Executive Chairman
Scott Maguire - Chief Executive Officer
Professor Gregory Gregoriadis PhD, DSc - Chief Scientific Officer
Dr Dmitry D Genkin - Non-Executive Director
Mr Colin William Hill, ACMA - Chief Financial Officer
Mr Firdaus Jal Dastoor, FCS - Non-executive Director
Mr Igor Nikolaev - Non-Executive director
For more information on Lipoxen's Directors click here
For information on Lipoxen's Senior Management click here
Major Shareholders
For investor information click here
Contact Information
Management Offices Lipoxen PLC
18 Pall Mall
2nd Floor
London
SW1Y 5LU
United Kingdom
Tel : +44(0) 20 7389 5015
Fax: +44(0) 20 7389 5011
Email info@lipoxen.com
Laboratories Lipoxen Technologies Ltd
London Bioscience Innovation Centre
2 Royal College Street
London
NW1 0NH
United Kingdom
Tel : +44(0) 207 691 3585
Corporate Information
Nominated Advisors
Singer Capital Markets Limited
One Hanover Street
London
W1S 1YZ
Company Brokers
Noble & Company Limited
5th Floor
120 Old Broad Street
London
EC2N 1AR
PR Advisors
Buchanan Communications Limited
45 Moorfields
London
EC2Y 9AE
Investors interested in Lipoxen Plc recently viewed:
- Access Pharmaceuticals (OTCBB: .ACCP)
- Alliance Pharma plc (AIM: APH)
- Amphion Innovations (LON: AMP)
- Asterand (LSE: ATD)
- Biocompatibles (LSE: BII)
- BioNeutral Group (OTCBB: .BONU)
- Bionomics (ASX: .BNO)
- Circadian Technologies Limited (ASX: .CIR)
- CogState (ASX: .CGS)
- Eco Animal Health Group Plc (AIM: EAH)
- Epistem (AIM: EHP)
- ImmuPharma PLC (AIM: IMM)
- Medical Australia Limited (ASX: MLA)
- Oxford Nutrascience (AIM: ONG)
- Renovo Group Plc (LSE: RNVO)
- Rexahn Pharmaceuticals (AMEX: RNN)
- Starpharma (ASX: .SPL)
- Stirling Products Limited (ASX: .STI)
